Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of an RXR agonist in treating drug resistant HER2+ cancers

Use of an RXR agonist in treating drug resistant HER2+ cancers

US Patent 11998521 · Granted Jun 4, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of diseases by concurrently eliciting remyelination effects and immuno2025
Combination therapy for the treatment of migraines2025
RXR agonist salt form, polymorphs thereof, and uses thereof2025
Methods of using RARγ agonists for cancer treatment2024
RXR agonist salt form, polymorphs thereof, and uses thereof2024
Use of an RXR agonist and taxanes in treating Her2+ cancers2024
Use of an RXR agonist and taxanes in treating Her2+ cancers2024
Use of an RXR agonist and taxanes in treating Her2+ cancers2024
Use of an RXR agonist and taxanes in treating Her2+ cancers2024
Methods of using RARγ agonists for cancer treatment2023
RAR selective agonists in combination with immune modulators for cancer immunoth2023
Receptor subtype and function selective retinoid and rexinoid compounds in combi2023